Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 05, 2025, titled "Press Release on the Unaudited Financial Results for the quarter ended 30th June, 2025".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals reported its consolidated Q1 FY26 results with revenue up 10% YoY to Rs. 1,711 Cr. Net profit grew 15% to Rs. 154 Cr, while EBITDA rose 20% to Rs. 288 Cr, giving an EBITDA margin of 17%. Profit before tax jumped 21% to Rs. 191 Cr, driven by broad-based growth across businesses. India Branded revenue rose 5% to Rs. 599 Cr, US Generics grew 13% to Rs. 523 Cr despite pricing pressure, and Ex-US International Generics surged 21% to Rs. 328 Cr. The API business grew marginally by 1% to Rs. 261 Cr. The company secured 6 ANDA approvals in the quarter (cumulative 223), launched 4 products in the US and 3 in India, and management cited a strong start to FY26 with expectations of improved operating leverage from new manufacturing facilities.
Double-digit growth in revenue, EBITDA, and profit reflects healthy operational momentum and is likely to be viewed positively by investors. Management's optimistic outlook on operating leverage from ramping up new facilities could support further upside in sentiment.